Tiagabine therapy for complex partial seizures: A dose-frequency study

Archives of Neurology

Volumn 54, Issue 5, 1997, Pages 595-601

  Sachdeo, Rajesh C ^a   Leroy, Robert F ^b   Krauss, Gregory L ^c   Drake Jr , Miles E ^d   Green, Philip M ^e   Leppik, Ilo E ^f   Shu, Vincent S ^g   Ringham, Gary L ^g   Sommerviile, Kenneth W ^g  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b Neurological Clinic of Texas   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e Kalamazoo Neurology   (United States)

^f MINCEP Epilepsy Care   (United States)

^g ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLORAZEPATE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; TIAGABINE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; AMNESIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031000352     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1997.00550170069016     Document Type: Article

References (13)

1. Braestrup C, Nielsen EB, Sonnewald U, et al. (R)-N-[4,4-bis(3-methyl-2-thienyl) but-3-en-1-yl]nipecotic acid binds with high affinity to the brain g- aminobutyric acid uptake carrier. J Neurochem. 1990;54:639-647.
2. Rekling JC, Jahnsen H, Laursen AM. The effect of two lipophilic gamma- aminobutyric acid uptake blockers in CA1 of the rat hippocampal slice. Br J Pharmacol. 1990;99:103-106.
3. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma- aminobutyric acid-uptake inhibitor in healthy subjects after single and multiple doses. Epilepsia. 1995;36:605-611.
4. Mengel HB. Tiagabine. Epilepsia. 1994;35(suppl 5):581-584.
5. Rowan AJ, Uthman B, Ahmann P, et al. Safety and efficacy of three dose levels of tiagabine HCI versus placebo as adjunctive treatment of complex partial seizures. Epilepsia. 1994;35(suppl 8):54.
6. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res. 1995;21:37-42.
7. So EL, Wolff D, Graves WM, et al Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res. 1995;22:221-226.
8. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsy Res. 1995;36(suppl 6):S14-S21.
9. Cramer JA, Mattson RH. General principles: compliance with antiepileptic drug therapy. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4th ed. New York, NY: Raven Press; 1995:149-159.
10. During M, Mattson R, Scheyer R, et al. The effect of tiagabine HCI on extracellular GABA levels in the human hippocampus. Epilepsia. 1992;33(suppl 3):83.
11. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Inst Intern Stat 1960;37:351-361.
12. SAS Institute Inc. SAS-STAT User's Guide: Version 6. 4th ed. Gary, NC: SAS Institute Inc; 1990.
13. Leppik IE. Tiagabine: the safety landscape. Epilepsia. 1995;36(suppl 6):S12-S13.